低剂量率γ射线杀伤肿瘤细胞机制的实验研究

用60Co源以1Gy/min剂量率照射Hela细胞,剂量分别为1、2、5、10、15Gy.用AnnexinV和PI双染法观察凋亡细胞形态;DNA梯形条带证实凋亡存在;克隆形成分析细胞增殖能力.结果显示:(1)Hela细胞凋亡率随照射剂量和时间的增加呈上升趋势,照射后168h组各剂量点凋亡率高于其他各时间组.2Gy以下时凋亡率改变不大,达5Gy时凋亡率显著增加,且达峰值(72.57±2.04)%(P＜0.001).(2)早期凋亡细胞,PS外翻,胞膜呈绿色荧光圈.凋亡晚期出现Annexin V-FITC及PI染色均阳性的外绿内红的细胞图像.坏死细胞则为红色.(3)凋亡细胞碎片呈"梯状"条带.(4)1Gy/min的剂量率照射,剂量为2-15Gy,克隆形成率由(58.95±0.36)%降至(1.67±0.35)%(P＜0.001).表明低剂量率γ射线照射可诱导Hela细胞凋亡,其凋亡率与照射剂量相关,在5Gy时凋亡率最高.     

基于采动和承压水作用下断层突水关键路径的力学分析

 断层突水是煤矿典型的动力灾害,是煤岩体在采动和承压水共同作用下失稳破坏过程。论文针对导水断层缩短了煤层和含水层距离特点,建立了断层突水的关键路径力学模型。将极限平衡理论和尖点突变理论引入断层突水分析,建立了承压水及采动影响下断层突水关键部位失稳破坏模型,获得了断层突水的力学判据,以及防突煤柱预留临界宽度。同时分析了断层参数、煤柱参数对突水条件的影响规律     

浅谈土壤源热泵系统的发展及其应用

概述了土壤源热泵系统的特点，阐述了土壤源热泵技术在国内外的发展、研究现状，最后介绍了土壤源热泵技术在发展中面临的问题及在制冷空调中的广阔应用前景。     

Solution structure of the sodium channel inactivation gate

The sodium channel initiates action potentials by opening in response to membrane depolarization. Fast channel inactivation, which is required for proper physiological function, is mediated by a cytoplasmic loop proposed to occlude the ion pore via a hinged lid mechanism with the triad IFM serving as a hydrophobic "latch". The NMR solution structure of the isolated inactivation gate reveals a stably folded core comprised of an alpha-helix capped by an N-terminal turn, supporting a model in which the tightly folded core containing the latch motif pivots on a more flexible hinge region to occlude the pore during inactivation. The structure, in combination with substituted cysteine mutagenesis experiments, indicates that the IFM triad and adjacent Thr are essential components of the latch and suggests differing roles for the residues of the IFMT motif in fast inactivation.     

Synthesis and biological evaluation of certain new thiazolopyrimidines

A series of 5-methyl-3-phenyl thiazolo[5,4-e][1,2,4]triazolo[1,5-c] pyrimidin-2-thiones and 5-methyl-3-phenyl thiazolo[5,4-e]pyrimidino[3,4-b][1,2,4]triazin-2-thiones were prepared as potential antimicrobial and antitumor agents. Some of the tested compounds showed promising activity. The detailed synthesis, spectroscopic and biological data are reported.     

Treatment outcome with radiation therapy after breast augmentation or reconstruction in patients with primary breast carcinoma

BACKGROUND: Analyses were performed to determine local control and cosmetic outcome of breast carcinoma patients with prosthetically augmented or reconstructed breasts who had received radiation therapy (RT). METHODS: Twenty-one newly diagnosed breast carcinoma patients with prosthetically augmented or reconstructed breasts were treated with external beam RT. All patients received whole breast RT (median dose, 50.4 gray [Gy]) and 19 were boosted to a median dose of 60.4 Gy. A median dose of 50.4 Gy was delivered to the regional lymph nodes in 12 patients. Tissue equivalent bolus material was used in six patients. Seventeen patients received adjuvant systemic therapy. Cosmetic results were evaluated at 3-6-month intervals. RESULTS: With a median follow-up of 32 months, good/excellent cosmetic results were observed in 71% of patients (100% in those with augmented breasts and 54% in those with reconstructed breasts). Four patients (19%) with fair/poor cosmetic outcomes required implant removal and/or revision. Multiple clinical and treatment-related factors were analyzed for their impact on cosmetic outcome. A worsened cosmetic result was observed with increasing stage (P = 0.076), breast reconstruction (vs. augmentation) (P = 0.030), and bolus application (P = 0.016). All patients with fair/poor cosmetic outcomes had time intervals from implant insertion to RT ranging from 53-213 days. Two patients developed an isolated local recurrence within the augmented breast. CONCLUSIONS: Patients with prosthetically augmented breasts can undergo RT and expect good/excellent cosmetic results. Patients with reconstructed breasts are at a significantly greater risk for cosmetic failure. This risk may be related to the higher percentage of patients with advanced disease, those who received bolus application, and those who received earlier delivery of RT (after the cosmetic procedure) in reconstructed breasts.     

Mammary ductal carcinoma in situ with microinvasion

BACKGROUND: The natural history of patients with intraductal carcinoma (DCIS) and microinvasion is poorly defined, and the clinical management of these patients, with particular reference to management of the axilla, has been controversial. Previous studies of this lesion have used varied and/or arbitrary criteria for the evaluation of microinvasion. METHODS: Thirty-eight DCIS lesions with microinvasion (n=29) or probable microinvasion (n=9), diagnosed during the period 1980-1996, were retrospectively analyzed after cases not treated with mastectomy and axillary lymph node dissection were excluded. Microinvasion was defined as a single focus of invasive carcinoma < or = 2 mm or up to 3 foci of invasion, each < or =1 mm in greatest dimension. RESULTS: The patients were all females with a mean age of 56.4 years. DCIS was of comedo (n=31) or papillary (n=7) subtype. Microinvasion was often associated with an altered, desmoplastic stroma (55%) or a lymphocytic infiltrate (39%). The foci of microinvasion ranged from 0.25 to 1.75 mm (mean, 0.6 mm), with an aggregate mean size of 1.1 mm (range, 0.25-2.25 mm). Foci of microinvasion, ranging from 1 to 3 (mean, 1.7), were adjacent to DCIS in 95.3% of cases. The extent of DCIS did not correlate with the number of foci of microinvasion. Axillary lymph node dissections yielded a mean of 19.3 lymph nodes (range, 7-38), and all lymph nodes were negative for metastasis. None of 33 patients, followed for a mean of 7.5 years (range, 1.0-14.4 years), developed local recurrence or metastasis. CONCLUSIONS: The cases of microinvasive carcinoma examined in this study, as defined above, were not associated with axillary lymph node metastases and appeared to be associated with an excellent prognosis. Further study is indicated to determine the appropriate management and long term prognosis of patients with this lesion.